Get started

Biotech

NOVN Swing trade or long?Our ABML Play seems to be working out so far. Here is another Gem that could work our similar. I love cheap stocks. NOVN is a clinical development-stage biotechnology company, which focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Checking Wallstreetzen, it appears to be backed by all the big boys like Vanguard, Blackrock, Renaissance etc... The company is developing a treatment for Molluscum Contagiosum, soon to be the only one FDA approved for Molluscum treatment if everything goes well. The readout for their B206 trial in June is expected to arrive with positive results from the data. Entry : $1.45 TP : $3 SL : $1 Let's see how this plays out. (Disclaimer, not financial advice) NASDAQ:NOVN
NLong
by jackohgorman
3
$OBLN Target 6.65 for 43.32% $OBLN Target 6.65 for 43.32% Or next add level is at 2.63 This one was fun today... still quite a ways to target but heading that way... — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
OLong
by SPYder_QQQueen_Trading
5
Ultimovacs ASCO 2021 60% ORR 30% CR #cancervaccineUltimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data • UV1/pembrolizumab results in 30% complete responses plus 30% partial responses • Good safety and tolerability profile supports use of UV1 in combination treatments • Data to be presented at ASCO and abstract to be discussed in webcast on May 20, 2021 Oslo, 19 May 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have been observed for at least 18 months and median observation time is 21 months. The results will be presented as an online poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. The 60% ORR (6 complete responses (CR); 6 partial responses (PR) from a 20-patient cohort) with 30% CR, clearly exceeds the response rate for pembrolizumab alone in advanced melanoma (33-37% ORR and 5-12% CR)*. The median progression-free survival for the UV1/pembrolizumab combination in the study was 18.9 months compared with 5.5-11.6 months* for pembrolizumab alone in advanced melanoma. The overall survival was 80%, with the median overall survival yet to be reached after 21-months of follow-up. “These very strong and exciting data further strengthen the foundation for our broad Phase II clinical program for UV1,” said Jens Bjørheim, Chief Medical Officer at Ultimovacs. “To show this level of beneficial clinical response while being safe and well-tolerated in combination with pembrolizumab underscores our development strategy to show that UV1 can provide a significant increase in therapeutic effect in a broad range of indications and combinations.” The rationale for the use of UV1 is that patients with advanced malignant melanoma often lack the relevant T cells to obtain durable benefits from the use of pembrolizumab alone. UV1 expands T cells that have the potential to increase the breadth and diversity of the immune response towards all parts of the tumor. The data comes from Ultimovacs’ open-label Phase I study (NCT03538314) and will be shown as a poster presentation at ASCO, to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The data also shows that the UV1/pembrolizumab combination is well tolerated, with adverse events largely restricted to low grade effects, mainly injection site reactions. “These data reinforce our conviction that UV1 can play a transformative role in the treatment of conditions such as malignant melanoma,” said Carlos de Sousa, CEO of Ultimovacs. “It suggests that UV1 in combination with checkpoint inhibitors like pembrolizumab can mobilize the immune system to fight cancer. This is very encouraging for melanoma patients and for those involved with the roll-out of Ultimovacs’ broader programs in solid cancers.” Webcast A corporate webcast will be held on Thursday 20 May 2021, 10:00 CEST. Carlos de Sousa, CEO of Ultimovacs and Jens Bjørheim, CMO, will discuss the ASCO abstract. It will be possible to submit written questions during the presentation. The webcast will be available subsequently on the company website;
ULong
by savepiginvest
On verge of major breakout (continued..)Bullish harmonic. Pattern in combination of low float stock such as KMPH is very bullish setup especially since the stock has been hovering around previous highest volume day of 1M shares traded. the stock has been hovering around 900k and reluctant to break 1M but the tutes are getting anxious as investor Samuel Braun decided to add to his position and steal shares from tutes attempting to manipulate stock price so they could add more. With KMPH’s new big blockbuster treatment for ADHD and main ingredient SDX which was recently announced to have received a Schedule IV narcotic (all other Stimulant based ADHD such as adderrall and Ritalin are schedule 2) the company looks to soon initiate KP879 which is comprised of SDX and will be first of kind treatment for stimulant use disorder (there are currently no treatments for SUD). Also Corium has told KMPH CEO Travis Mickle they would like to see kmph get Azstarys label expansion for treatment of ADHD in pre-schoolers! Exciting times ahead for Kempharm team. Disclosure: i am long KMPH. I am not a licensed financial analyst and this information is to be used for educational purposes only.
KLong
by follow_the_money
AION Formulations Kill Breast Cancer Cells Through Multiple PathBullish MACD cross (technical buy signal) + monster news!! Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways LONDON and TORONTO, May 18, 2021 /PRNewswire/ -- Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica"), and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a subsidiary of Aion. The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while Aion's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways. Stephen D. Barnhill, M.D., CEO of Apollon, commented, "Cannabinoids have been seen to exert 'antitumor' effects by a number of different means, including killing cancer cells directly as well as inhibiting transformed cell growth and tumor metastasis. Apollon Jamaica, using results from its proprietary artificial intelligence based analysis on strain genetics, has cultivated and processed certain of its proprietary medical cannabis products with cancer treatment expressly in mind. We are excited that our formulations have been validated via independent laboratory testing to kill HER2+ breast cancer cells in 3D cell culture through direct cytotoxicity." Dr. Herbert A. Fritsche, Chief Science Officer of Aion and former Professor and Director of Clinical Chemistry at the University of Texas, MD Anderson Cancer Center, stated, "Our recent medicinal mushroom formulation testing demonstrated that two formulations, AION F7 and AION F8, when used together, showed high efficacy in killing HER2+ breast cancer cells via immune stimulated cytotoxicity by T-cells and macrophages. This result suggests that these Aion medicinal mushroom formulations have a similar effectiveness as Trastuzumab (Herceptin, Roche), a monoclonal antibody treatment." Added Dr. Barnhill, "It is our theory that use of a combination of anticancer therapies, especially ones involving separate treatment pathways, may have advantages over single-agent-based strategies as they may allow simultaneous or serial targeting of tumor growth, progression, and/or spreading at different levels with efforts to kill cancer cells. As a part of the independent laboratory testing, we have demonstrated that, when Apollon's medical cannabis formulations are used together with Aion's medicinal mushroom formulations, nearly 100% of HER2+ breast cancer cells in 3D cell culture are killed through multiple different pathways. Pursuant to the Research & Development and the Retail -Therapeutic licences issued to Apollon, we intend to have Jamaican physicians begin treating patients who have HER2+ breast cancer in Jamaica where each company's formulations can be available by physician prescription. This will allow us to corroborate these exciting laboratory results by observing the results of treatment in human patients." Worldwide, breast cancer is the most common cancer in women and accounts for the most cancer related deaths. In 2019, the breast cancer market totalled over US$20 billion, with 68% of therapies sold targeting HER2 or CDK4/6. Market research analysts Paul Wilcock and Rachel M. Webster of Decision Resources Group (part of Clarivate, London, UK) have predicted that the breast cancer market will grow 9% annually and be over US$47 billion by 2029. Commented Mr. Paul Burke, Chairman and CEO of Apollon Jamaica, "These test results and the plan to begin treatments in Jamaica are very exciting developments. Traditional chemotherapy, radiation and surgery cancer treatment protocols are expensive and require a great deal of infrastructure. As a result many women in Jamaica and worldwide have gone without, or with only limited, treatment." The Apollon Jamaica Chairman went on to say, "The combined formulations of Apollon and Aion are expected to be comparatively inexpensive, providing an opportunity for all women to have their breast cancer treated. I look forward to collaborating with Aion with regard to our shared vision to bring these formulations to market as quickly as possible and in a manner that allows all Jamaican women with HER2+ breast cancer, as well as, women traveling from international locations to Jamaica as medical tourists for our treatment, to have access to quality care." The testing occurred as a part of a Joint Testing Agreement between the parties and was authorized in accordance with Apollon Jamaica's Research & Development licence issued by the Jamaican government's Cannabis Licensing Authority (CLA). In the performance of services under the Joint Testing Agreement, each party confined its activities to those permitted by applicable law, with CLA licensed Apollon Jamaica performing medical cannabis activities and AI Pharma performing services involving functional medicinal mushrooms. Mushroom formulations containing psilocybin or psilocin, which comes from psychedelic mushrooms, were not included as a part of the joint testing. AI Pharma currently has an agreement with Apollon Jamaica to license equipment and an agreement with Doc's Place International, Inc. to sublease space in order that AI Pharma can perform cultivation, research and development, processing and treatment services in Jamaica with regard to its medicinal mushrooms formulations. The companies next expect to negotiate a joint license agreement involving their formulations and intellectual property whereby AI Pharma may exclusively use Apollon Jamaica's medical cannabis formulations in their combined product lines in the US and Canada, and Apollon may exclusively use certain of Aion's medicinal (non-psilocybin) mushroom products in their combined product lines in Europe and Jamaica, where legal. This structure would allow Apollon to benefit from Aion's sales in the US and Canada, where Apollon Jamaica is unable to sell medical cannabis under current US and UK law. In both instances, medical care will be done by physicians and psychiatrists authorized to prescribe medications and treat patients.
CSE:AIONLong
by wealth_bakery
ADDED to $SYRS New Target 8.81 for 27.68% $SYRS Target 8.81 for 27.68% Or next add level is at 4.99 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
SLong
by SPYder_QQQueen_Trading
2
Biotech Sector Likely To Bounce It's been a rough ride for bios lately, but a reversal could be coming very soon. As you can see in the chart, $XBI, the biotech ETF that I like, has fallen to an important VWAP and to the 50% retracement. Today we bounced off of that level, forming a sort of hammer candle on this Heikin Ashi chart. This fund is also currently at the bottom of the daily RSI, which historically is a good sign. This could mean we see a bounce soon, possibly to $150 within the next couple of weeks. I may post more on biotechs now that they should be getting hotter, so be sure to like and follow for more ideas like this :) Good Luck!
AMEX:XBILong
by Investor4321
1
Under Major revaluationWouldn't be surprised to see this stock break all time highs in next few months and in the next 12-months $50+. * Key notes: 2nd generation Covid Vaccine sponsored by NIAID that's being conducted through infectious diseases clinical research consortium (IDCRC). Established collaboration with Gilead Sciences to develop a vaccine-based immunotherapy as part of Gilead's efforts to find a 'curative treatment for human immunodeficiency virus" (HIV) infection, and received $60 million in proceeds as part of the collaboration for GRTS HIV candidate. More candidates in clinic on their website. Very bullish accumulation going on after test of $35 (red horizontal line). See my other picks! $KMPH $VBIV $BCRX $GRTS Disclaimer: This is not a buy or sell recommendation. I am not a financial analyst. This information should be used for educational purposes only.
GLong
by follow_the_money
BACK IN $IBIO @ 1.57 Target 1.91 for 21.66% $IBIO Target 1.91 for 21.66% Or next add level is at 1.23 Good fun!! Sold at 2.19 two days ago and back in at 1.57... let's go!! — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
ILong
by SPYder_QQQueen_Trading
2
ADDED to $SYRS New Target 9.22 for 26.13% $SYRS Target 9.22 for 26.13% Or next add level is at 5.40 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
SLong
by SPYder_QQQueen_Trading
3
$RMED entry PTs 3.45-3.50 (ER next Tues: 5/11/2021) PTs 4-9Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
RLong
by UnknownUnicorn19246015
$VXRT entry PT 7-8 PT Target PTs 14-17-22Trend-base Fib Extension... Why Vaxart Stock Is Surging Today Investors are excited about the company's experimental COVID-19 vaccine. What happened Shares of Vaxart (NASDAQ:VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%. So what A phase 1 study showed Vaxart's vaccine to potentially be protective against COVID-19, as well as a broad array of other coronavirus-induced illnesses, such as SARS, MERS, and the common cold. "Our vaccine's immune response appears very different than that seen from the leading injectables: mucosal antibodies rather than serum antibodies, and more potent T-cell responses," Vaxart CEO Andrei Floroiu said in a press release. T-cells are a type of white blood cells that can seek out and kill virus-infected cells. They are a vital part of the body's ability to generate an adaptive immune response to specific pathogens. Vaxart's drug produced a stronger T-cell response than Pfizer and Moderna's injectable vaccines, according to Vaxart's chief scientific officer, Dr. Sean Tucker. Now what Should Vaxart's vaccine candidate prove to be safe and effective in later-stage clinical trials, it could become a welcomed new tool in the battle against COVID-19. In such a scenario, the drug would also provide Vaxart with a powerful new revenue and profit driver. Joe Tenebruso (TMFGuardian)
NASDAQ:VXRT
by UnknownUnicorn19246015
ZOM hits lows and bounces back hardI will admit if a trade doesn't come to what I think it will do I'll say im wrong, but that's the beauty of tradingview and how we can share ideas. I still remain skeptical of the current price action and have give a range of price movement of the current price. As a trader watching on the sidelines I still believe for a new/long term trade is wait till earnings. This movement up is unknown why its pumping but a few reasons may be the cause Why is this pumping? -Whole market is recovering at this time and biotech/pennystocks are feeling some love which were one of the worst hit sectors. -Past buyers bought the dip and has had an amazing bounce back, which I will talk about in the TA portion. -The sentiment around ZOM was negative people panic sold from $1.15 too .73, which caused the sellers to be exhausted. With no more sellers the price rebounded and fomo struck. TA: Its interesting cause the chart goes aganist the news, so an idea of this is a short squeeze to exit positions. Who knows -April 22, we skyrocketed towards the 50ema and held causing a bullish reversal in the RSI as it held -RSI leads bullish with the current movement of the stock -Resistance is at 1.41, but could say its at 1.18 with past high or go off the emas, which is at 1.13 and 1.29 -Support would be at the 50 ema .97/.96 or slightly before at 1.01 which could be a dip opportunity. -If the trade goes south you could experience a 29%-74% lost with an upside of 124% going back to ath Final thoughts I'll remain skeptical of this pump till er, since again it could be a pump to have people fomo and sell into the buyers or just exhaustion from the months of downward movement. With TA however it remains bullish/neutral
Z
by nathanielx9